Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Interleaved With ECT for Depression
NCT04082858Phase 1Terminated
- Sponsor
- St Patrick's Mental Health Services
- Start
- Jan 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of ketamine in major depressive disorder (MDD) and bipolar disorder (BD) (2 arms), sponsored by St Patrick's Mental Health Services. Primary endpoint: Montgomery Asberg Depression Rating Scale at 18 weeks. Started Jan 2020; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT04082858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082858.